Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Other Non Operating Income (2019 - 2025)

Rein Therapeutics filings provide 7 years of Other Non Operating Income readings, the most recent being -$20000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 94.92% year-over-year to -$20000.0, compared with a TTM value of $48000.0 through Dec 2025, up 152.63%, and an annual FY2025 reading of $48000.0, up 152.63% over the prior year.
  • Other Non Operating Income hit -$20000.0 in Q4 2025 for Rein Therapeutics, up from -$89000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $336000.0 in Q4 2022, with the low at -$394000.0 in Q4 2024.
  • Median Other Non Operating Income over the past 5 years was $81500.0 (2021), compared with a mean of $76111.1.
  • The sharpest move saw Other Non Operating Income surged 3800.0% in 2023, then plummeted 704.08% in 2024.
  • Year by year, Other Non Operating Income stood at $71000.0 in 2021, then soared by 373.24% to $336000.0 in 2022, then plummeted by 114.58% to -$49000.0 in 2023, then crashed by 704.08% to -$394000.0 in 2024, then surged by 94.92% to -$20000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$20000.0, -$89000.0, and $49000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.